ORLANDO, FL USA (UroToday.com) - Although BCG remains the intravesical therapy of choice, after TURBT, for high-grade non-muscle invasive bladder carcinomas (NMIBC), a recurrence and progression rate of up to 40% occurs after induction treatment. BCG failure likely can be attributed, at least partially, to inherent tumoral characteristics.
The research group aims to seek out differences in gene expression profile between tumors that recurred and those free from recurrence after induction BCG.

FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST

Did you find this article relevant? Subscribe to UroToday-GUOncToday!

The fields of GU Oncology and Urology are advancing rapidly including new
treatments, enrolling clinical trials, screening and surveillance
recommendations along with updated guidelines. Join us as one of our
subscribers who rely on UroToday as their must-read source for the
latest news and data on drugs. Sign up today for blogs, video
conversations, conference highlights and abstracts from peer-review
publications by disease and condition delivered to your inbox and read
on the go.

The authors showed, that compared to BCG-responsive tumors, high-grade NMIBCs that recur after BCG treatment have increased expression of genes implicated in bladder cancer growth and survival, invasion, response to therapy, and metastasis.